NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
GeoVax Highlights Government Investment in Orthopox Preparedness and GEO-MVA Vaccine Development
GeoVax highlights the U.S. government's recent procurement of smallpox vaccine as validation of sustained investment in orthopox preparedness. The company is advancing GEO-MVA, a U.S.-manufactured MVA vaccine for mpox and smallpox, through an expedited regulatory pathway with a Phase 3 study starting in Q4 2026.
GeoVax comments on the U.S. government's recent procurement of ACAM2000 smallpox vaccine, reinforcing the strategic importance of orthopox preparedness and long-term investment in vaccine manufacturing capacity.
It demonstrates the government's ongoing commitment to maintaining the Strategic National Stockpile and sustaining multiple medical countermeasures against smallpox and mpox threats, which validates the need for diversified vaccine supply and resilient manufacturing.
GEO-MVA is GeoVax's Modified Vaccinia Ankara (MVA)-based vaccine candidate for protection against mpox and smallpox. It is designed to be a U.S.-manufactured, non-replicating MVA vaccine that expands domestic manufacturing capacity and strengthens orthopoxvirus vaccine supply resilience.
Following positive scientific advice from the EMA, GeoVax is pursuing an expedited strategy using immunobridging to an approved MVA vaccine. The pivotal Phase 3 study is scheduled to start in Q4 2026, with data readout from the immunobridging portion anticipated by mid-2027.
GeoVax Labs, Inc. is developing GEO-MVA, with regulatory guidance from the European Medicines Agency (EMA). The program supports U.S. government biodefense and public health preparedness efforts.
GeoVax believes the continued federal investment in orthopox preparedness strongly supports accelerated development of GEO-MVA through its expedited regulatory pathway and expansion of U.S.-based MVA manufacturing.
GEO-MVA aims to provide an additional U.S.-manufactured, non-replicating MVA vaccine option, enhancing supply resilience and domestic manufacturing capacity for orthopoxvirus preparedness.
The Phase 3 study is scheduled to initiate in the fourth quarter of 2026.